|
|
|
Fiscal Period: March
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Capitalization1 |
4 098 266 | 7 029 161 | 5 153 364 | 6 229 971 | - | - |
| Entreprise Value (EV)1 |
4 708 760 | 12 054 743 | 9 609 054 | 9 862 522 | 9 014 983 | 8 549 620 |
| P/E ratio |
21,7x | 40,0x | 118x | 16,6x | 21,7x | 16,5x |
| Yield |
3,47% | 3,98% | 5,44% | 4,52% | 4,76% | 4,76% |
| Capitalization / Revenue |
2,31x | 3,35x | 1,57x | 1,95x | 1,79x | 1,77x |
| EV / Revenue |
2,66x | 5,75x | 2,92x | 3,08x | 2,72x | 2,56x |
| EV / EBITDA |
10,8x | 25,3x | 14,0x | 9,23x | 8,20x | 7,29x |
| Price to Book |
2,03x | 1,36x | 1,09x | 1,20x | 1,19x | 1,18x |
| Nbr of stocks (in thousands) |
790 713 | 1 554 780 | 1 557 849 | 1 563 355 | - | - |
| Reference price (JPY) |
5 183 | 4 521 | 3 308 | 3 985 | 3 779 | 3 779 |
| Last update |
05/14/2018 | 05/14/2019 | 05/13/2020 | 05/11/2021 | 06/10/2021 | 06/10/2021 |
|
1 JPY in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: March
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Net sales1 |
1 770 531 | 2 097 200 | 3 291 200 | 3 197 812 | 3 309 924 | 3 335 948 |
| EBITDA1 |
437 460 | 477 415 | 684 057 | 1 068 940 | 1 098 899 | 1 171 992 |
| Operating profit (EBIT)1 |
241 789 | 205 000 | 100 400 | 509 269 | 504 822 | 585 331 |
| Operating Margin |
13,7% | 9,77% | 3,05% | 15,9% | 15,3% | 17,5% |
| Pre-Tax Profit (EBT)1 |
217 205 | 94 896 | -60 754 | 366 235 | 428 723 | 504 152 |
| Net income1 |
186 886 | 109 100 | 44 200 | 376 005 | 315 701 | 385 116 |
| Net margin |
10,6% | 5,20% | 1,34% | 11,8% | 9,54% | 11,5% |
| EPS2 |
239 | 113 | 28,0 | 241 | 174 | 229 |
| Dividend per Share2 |
180 | 180 | 180 | 180 | 180 | 180 |
| Last update |
05/14/2018 | 05/14/2019 | 05/13/2020 | 05/11/2021 | 06/10/2021 | 06/10/2021 |
|
1 JPY in Million 2 JPY Estimates
|
|
|
|
|
Fiscal Period: March
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Net Debt1 |
610 494 | 5 025 582 | 4 455 690 | 3 632 551 | 3 100 539 | 2 635 176 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
1,40x | 10,5x | 6,51x | 3,40x | 2,82x | 2,25x |
| Free Cash Flow1 |
471 196 | -2 507 219 | 961 871 | 617 401 | 861 006 | 828 355 |
| ROE (Net Profit / Equities) |
9,60% | 3,00% | 0,90% | 7,60% | 6,76% | 8,71% |
| Shareholders' equity1 |
1 946 729 | 3 636 667 | 4 911 111 | 4 947 434 | 4 672 303 | 4 421 389 |
| ROA (Net Profit / Asset) |
5,13% | 1,06% | -0,46% | 2,85% | 3,53% | 3,95% |
| Assets1 |
3 640 511 | 10 334 963 | -9 710 018 | 13 209 937 | 8 936 865 | 9 758 425 |
| Book Value Per Share2 |
2 557 | 3 319 | 3 032 | 3 309 | 3 177 | 3 216 |
| Cash Flow per Share2 |
490 | 397 | 403 | 599 | 568 | 547 |
| Capex1 |
67 005 | 77 677 | 127 082 | 111 206 | 186 370 | 184 245 |
| Capex / Sales |
3,78% | 3,70% | 3,86% | 3,48% | 5,63% | 5,52% |
| Last update |
05/14/2018 | 05/14/2019 | 05/13/2020 | 05/11/2021 | 06/10/2021 | 06/10/2021 |
|
1 JPY in Million 2 JPY Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
Takeda says it may double imports of Moderna shots to help accelerate Japan vaccination |
Capitalization (JPY) 5 914 444 262 023 Capitalization (USD) 53 877 389 065 Net sales (JPY) 3 291 200 000 000 Net sales (USD) 29 989 414 400 Number of employees 47 495 Sales / Employee (JPY) 69 295 715 Sales / Employee (USD) 631 423 Free-Float capitalization (JPY) 5 859 451 301 292 Free-Float capitalization (USD) 53 376 432 930 Avg. Exchange 20 sessions (JPY) 21 006 527 587 Avg. Exchange 20 sessions (USD) 191 411 479 Average Daily Capital Traded 0,4%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
